IL289066A - תכשירים ושיטות לטיפול במנת יתר חריפה של קנבינואיד באמצעות אנטגוניסט לקולטן קנבינואיד - Google Patents

תכשירים ושיטות לטיפול במנת יתר חריפה של קנבינואיד באמצעות אנטגוניסט לקולטן קנבינואיד

Info

Publication number
IL289066A
IL289066A IL289066A IL28906621A IL289066A IL 289066 A IL289066 A IL 289066A IL 289066 A IL289066 A IL 289066A IL 28906621 A IL28906621 A IL 28906621A IL 289066 A IL289066 A IL 289066A
Authority
IL
Israel
Prior art keywords
cannabinoid
compositions
methods
receptor antagonist
overdose
Prior art date
Application number
IL289066A
Other languages
English (en)
Original Assignee
Opiant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/704,699 external-priority patent/US20200179271A1/en
Application filed by Opiant Pharmaceuticals Inc filed Critical Opiant Pharmaceuticals Inc
Publication of IL289066A publication Critical patent/IL289066A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL289066A 2019-06-18 2021-12-16 תכשירים ושיטות לטיפול במנת יתר חריפה של קנבינואיד באמצעות אנטגוניסט לקולטן קנבינואיד IL289066A (he)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962862830P 2019-06-18 2019-06-18
US201962862832P 2019-06-18 2019-06-18
US16/704,699 US20200179271A1 (en) 2018-12-07 2019-12-05 Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
US202063037351P 2020-06-10 2020-06-10
PCT/US2020/038211 WO2020257333A1 (en) 2019-06-18 2020-06-17 Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist

Publications (1)

Publication Number Publication Date
IL289066A true IL289066A (he) 2022-02-01

Family

ID=74040920

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289066A IL289066A (he) 2019-06-18 2021-12-16 תכשירים ושיטות לטיפול במנת יתר חריפה של קנבינואיד באמצעות אנטגוניסט לקולטן קנבינואיד

Country Status (4)

Country Link
EP (1) EP3986396A4 (he)
AU (1) AU2020295410A1 (he)
IL (1) IL289066A (he)
WO (1) WO2020257333A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020296012A1 (en) 2019-06-18 2022-01-20 Indivior Uk Limited Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
WO2013068371A1 (en) * 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
CN106659723A (zh) * 2014-07-09 2017-05-10 爱普制药有限责任公司 用于治疗神经病症的方法
GB2551986A (en) * 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
AU2019391109A1 (en) * 2018-12-07 2021-06-24 Opiant Pharmaceuticals, Inc. Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist

Also Published As

Publication number Publication date
WO2020257333A1 (en) 2020-12-24
EP3986396A4 (en) 2023-08-02
AU2020295410A1 (en) 2022-01-20
EP3986396A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
IL283693A (he) תרכובות ושיטות לטיפול במנת יתר חריפה של קנאבינואידים עם אנטגוניסט לקולטן קנאבינואידי
IL324507A (he) תרכובת אגוניסט לקולטן thr-beta ושיטה להכנתה ולשימוש בה
ZA201906107B (en) Kappa opioid receptor antagonists and products and methods related thereto
SG11202104436TA (en) Methods and apparatuses for copyright allocation for blockchain-based work
IL274134A (he) שיטות לטיפול או מניעת אסטמה על ידי מתן אגוניסט ל- il-4r
IL292692B1 (he) אנטגוניסטים ל–Mrgprx2 ושימושים שלהם
GB201905552D0 (en) Antagonists
PT3814341T (pt) Inibidores de recetor erbb
GB201911187D0 (en) Receptor
IL277634A (he) נוגדן אגוניסט קולטן לפטין לשימוש בטיפול בהפרעה בתפקוד מטבולי או בהיפולפטינמיה
IL287275A (he) שיטות לטיפול או מניעת אסטמה על ידי מתן אגוניסט ל il-33
IL286760A (he) שיטת חישוב כמות מאפיינים, תוכנית חישוב כמות מאפיינים ומכשיר חישוב כמות מאפיינים, שיטת סינון, תוכנית סינון ומכשיר סינון, שיטה ליצירת תרכובת, תוכנית ליצירת תרכובת ומכשיר ליצירת תרכובת
ZA202201157B (en) Selective estrogen receptor degrader
SI3736459T1 (sl) Sidrna točka
SG11202108625WA (en) Compounds and methods for reducing kcnt1 expression
GB201903832D0 (en) New compounds and methods
GB202000302D0 (en) Diverter tool and associated methods
IL289066A (he) תכשירים ושיטות לטיפול במנת יתר חריפה של קנבינואיד באמצעות אנטגוניסט לקולטן קנבינואיד
IL274435A (he) אפטמר ל–adamts5, ושימוש לאפטמר ל–adamts5
IL293544A (he) שיטות לטיפול copd ע" י מתן il-33 אנטגוניסט
IL291396A (he) מעכבי mll1 ותרופות אנטי-סרטניות
GB201816639D0 (en) GLP-1 Receptor Antagonist
IL289068A (he) תכשירים ושיטות לטיפול בתסמונת היפרמזיס קנבינואידית באמצעות אנטגוניסט של קולטן קנבינואיד
HK40074663A (en) Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
GB2578474B (en) Collating machine and method